Allogene Therapeutics gets grant for patent granted for CD19-specific CARS resistant to rituximab

14h ago, source: Pharmaceutical Technology

Discover the groundbreaking patent by Allogene Therapeutics for CD19-specific CARs resistant to rituximab binding. Learn about the innovative methods and features of these engineered immune cells.

Allogene Therapeutics Announces Q2 Investor Conference Participation

14d ago, source:

SOUTH SAN FRANCISCO, Calif., April 09, 2024 (GLOBE NEWSWIRE) -- (Nasdaq: ALLO), a clinical-stage biotechnology company ...

Allogene Therapeutics, Inc. (NASDAQ:ALLO) Q4 2023 Earnings Call Transcript

1mon ago, source: InvestingChannel on MSN

Allogene Therapeutics, Inc. (NASDAQ:ALLO) Q4 2023 Earnings Call Transcript March 14, 2024 Allogene Therapeutics, Inc. isn't ...

How Allogene (ALLO) Stock Stands Out in a Strong Industry

15d ago, source: Zacks.com on MSN

One stock that might be an intriguing choice for investors right now is Allogene Therapeutics, Inc. ALLO. This is because this security in the Medical - Biomedical and Genetics space is seeing solid ...

PFIZER INC's Net Worth

1d ago, source: Benzinga.com

PFIZER INC has an estimated net worth of $2.44 Billion. This is based on reported shares across multiple companies, which include BioAtla, Inc., Viatris Inc, Cerevel Therapeutics Holdings, Inc ...

Allogene Therapeutics Inc ALLO

13d ago, source: Morningstar

We sell different types of products and services to both investment professionals and individual investors. These products and services are usually sold through license agreements or subscriptions ...

Allogene Therapeutics Announces Q2 Investor Conference Participation

14d ago, source: Nasdaq

JPM Securities Life Sciences Conference Tuesday, May 14, 20246:00am PT/9:00am ET Any available webcasts will be posted to the Company's website at www.allogene.com under the Investors tab in the ...

Allogene Therapeutics Inc (ALLO)

15d ago, source: Investing

Allogene Therapeutics (NASDAQ:ALLO), the biotechnology company specializing in allogeneic CAR T therapies, has recently provided an update on its clinical trials and financial ...

Allogene Therapeutics Inc ALLO

8d ago, source: Morningstar

We sell different types of products and services to both investment professionals and individual investors. These products and services are usually sold through license agreements or subscriptions ...

Allogene Therapeutics Inc (ALLO)

22d ago, source: Investing

Gilead Sciences’ GILD Kite announced positive top-line results from the primary analysis of the global phase III multicenter study, ZUMA-7. ZUMA-7 evaluated a one-time ...